Jeff Yass’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.02M Sell
33,900
-156,500
-82% -$15M ﹤0.01% 5407
2026
Q2
$16.9M Buy
190,400
+177,300
+1,353% +$12.9M ﹤0.01% 2652
2026
Q1
$661K Buy
13,100
+5,300
+68% +$200K ﹤0.01% 8944
2025
Q4
$256K Buy
+7,800
New +$204K ﹤0.01% 10317
2025
Q2
– Sell
-23,200
Closed -$374K – 13694
2025
Q1
$374K Buy
+23,200
New +$483K ﹤0.01% 9568

Other funds holding SYRE

Jeff Yass's SYRE Position: Q3 2026 in Review

Jeff Yass increased its Spyre Therapeutics (SYRE) stake by 12% in Q3 2026, buying an estimated $436K and bringing the position to 43,849 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4893.

Jeff Yass first reported a position in SYRE in Q2 2017 and has held it in 19 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Jeff Yass held 43,849 shares of Spyre Therapeutics worth $3.9M as of Q3 2026.
  • Jeff Yass bought 4,538 Spyre Therapeutics shares in Q3 2026, an estimated $436K.
  • Spyre Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #4893 holding.
  • Jeff Yass first reported a position in Spyre Therapeutics in Q2 2017 and has held it in 19 quarters since.
  • 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.